Emergent Biosolutions EBS Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Emergent Biosolutions in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The official record: Emergent Biosolutions’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Emergent Biosolutions's accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Emergent Biosolutions's accounts receivable?
- Emergent Biosolutions (EBS) reported accounts receivable of $121.6M in Q1 2026.
- How has Emergent Biosolutions's accounts receivable changed year-over-year?
- Emergent Biosolutions's accounts receivable decreased by 40.3% year-over-year, from $203.7M to $121.6M.
- What is the long-term trend for Emergent Biosolutions's accounts receivable?
- Over 5 years (2020 to 2025), Emergent Biosolutions's accounts receivable has grown at a -18.3% compound annual growth rate (CAGR), from $230.9M to $84.2M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.